TABLE 3.
Baseline Characteristics of Study Population of Analysis I
| Children, n = 2978 (2.24%) | Adults, n = 86,663 (65.23%) | Elderly, n = 43,209 (32.52%) | Total, n = 132,850 (100%) | |
|---|---|---|---|---|
| Geographic region | ||||
| Europe | 1340 (45.0%) | 37,991 (43.8%) | 24,249 (56.1%) | 63,580 (47.9%) |
| Asia (excluding China) | 1286 (43.2%) | 22,907 (26.4%) | 7903 (18.3%) | 32,096 (24.2%) |
| China | 345 (11.6%) | 25,431 (29.3%) | 11,011 (25.5%) | 36,787 (27.7%) |
| Africa | 7 (0.2%) | 334 (0.4%) | 46 (0.1%) | 387 (0.3%) |
| Concentration | ||||
| Iopromide 300 | 2209 (74.2%) | 54,085 (62.4%) | 28,275 (65.4%) | 84,569 (63.7%) |
| Iopromide 370 | 769 (25.8%) | 32,578 (37.6%) | 14,934 (34.6%) | 48,281 (36.3%) |
| Sex | ||||
| Male | 1629 (54.7%) | 49,186 (56.8%) | 24,171 (55.9%) | 74,986 (56.4%) |
| Female | 1349 (45.3%) | 37,477 (43.2%) | 19,038 (44.1%) | 57,864 (43.6%) |
| Race | ||||
| Asian | 838 (28.1%) | 34,673 (40.0%) | 14,110 (32.7%) | 49,621 (37.4%) |
| White | 210 (7.1%) | 4083 (4.7%) | 1889 (4.4%) | 6182 (4.7%) |
| Black | 1 (<0.1%) | 14 (<0.1%) | 9 (<0.1%) | 24 (<0.1%) |
| Other | 3 (0.1%) | 117 (0.1%) | 44 (0.1%) | 164 (0.1%) |
| Not specified | 1926 (64.7%) | 47,776 (55.1%) | 27,157 (62.9%) | 76,859 (57.9%) |
| Concomitant disease | 997 (33.5%) | 38,801 (44.8%) | 22,607 (52.3%) | 62,405 (47.0%) |
| Hypertension arterial | 23 (0.8%) | 9879 (11.4%) | 6817 (15.8%) | 16,719 (12.6%) |
| Coronary heart disease | 25 (0.8%) | 5996 (6.9%) | 5222 (12.1%) | 11,243 (8.5%) |
| Diabetes mellitus | 5 (0.2%) | 5574 (6.4%) | 4805 (11.1%) | 10,384 (7.8%) |
| Reduced general condition | 215 (7.2%) | 3980 (4.6%) | 2737 (6.3%) | 6932 (5.2%) |
| Specific contrast media risk factor | 98 (3.3%) | 3347 (3.9%) | 1462 (3.4%) | 4907 (3.7%) |
| Allergy | 71 (2.4%) | 2467 (2.8%) | 1021 (2.4%) | 3559 (2.7%) |
| Asthma | 15 (0.5%) | 489 (0.6%) | 316 (0.7%) | 820 (0.6%) |
| Contrast media reaction | 16 (0.5%) | 515 (0.6%) | 186 (0.4%) | 717 (0.5%) |
| Other | 315 (10.6%) | 11,715 (13.5%) | 7304 (16.9%) | 19,334 (14.6%) |
| None specified | 686 (23.0%) | 17,004 (19.6%) | 7135 (16.5%) | 24,825 (18.7%) |
| Premedication | ||||
| Corticosteroids | 138 (4.6%) | 7297 (8.4%) | 3067 (7.1%) | 10,502 (7.9%) |
| H1/H2 blocker | 64 (2.1%) | 2284 (2.6%) | 934 (2.2%) | 3282 (2.5%) |
| H1/H2 blocker or corticosteroids | 0 | 22 (<0.1%) | 12 (<0.1%) | 34 (<0.1%) |
| Other | 103 (3.5%) | 3756 (4.3%) | 1936 (4.5%) | 5795 (4.4%) |
| None specified | 6 (0.2%) | 185 (0.2%) | 61 (0.1%) | 252 (0.2%) |
| Injection route | ||||
| Intravenous | 2852 (95.8%) | 68,275 (78.8%) | 33,892 (78.4%) | 105,019 (79.1%) |
| Intra-arterial | 126 (4.2%) | 18,388 (21.2%) | 9317 (21.6%) | 27,831 (20.9%) |
| Examination region* | ||||
| Abdomen | 445 (14.9%) | 16,943 (19.6%) | 7884 (18.2%) | 25,272 (19.0%) |
| Cardiac/cardiac vessels | 76 (2.6%) | 15,539 (17.9%) | 7213 (16.7%) | 22,828 (17.2%) |
| Thorax | 365 (12.3%) | 8207 (9.5%) | 4478 (10.4%) | 13,050 (9.8%) |
| Pelvis | 203 (6.8%) | 5284 (6.1%) | 2245 (5.2%) | 7732 (5.8%) |
| Head/brain | 425 (14.3%) | 4118 (4.8%) | 1555 (3.6%) | 6098 (4.6%) |
| Kidney/renal vessels | 161 (5.4%) | 2908 (3.4%) | 1069 (2.5%) | 4138 (3.1%) |
| Neck | 109 (3.7%) | 1893 (2.2%) | 564 (1.3%) | 2566 (1.9%) |
| Blood vessels | 53 (1.8%) | 1053 (1.2%) | 637 (1.5%) | 1743 (1.3%) |
| Limbs | 10 (0.3%) | 227 (0.3%) | 149 (0.3%) | 386 (0.3%) |
| Joints | 3 (0.1%) | 29 (<0.1%) | 11 (<0.1%) | 43 (<0.1%) |
| Other | 55 (1.8%) | 662 (0.8%) | 218 (0.5%) | 935 (0.7%) |
| Not specified | 2 (<0.1%) | 3 (<0.1%) | 3 (<0.1%) | 8 (<0.1%) |
| Missing | 1607 (54.0%) | 39,465 (45.5%) | 21,556 (49.9%) | 62,628 (47.1%) |
| Indication* | ||||
| Tumor/suspicion of tumor | 476 (16.0%) | 16,508 (19.0%) | 8088 (18.7%) | 25,072 (18.9%) |
| Pain | 175 (5.9%) | 5212 (6.0%) | 1648 (3.8%) | 7035 (5.3%) |
| Posttherapy control | 117 (3.9%) | 4509 (5.2%) | 2341 (5.4%) | 6967 (5.2%) |
| Staging | 137 (4.6%) | 3194 (3.7%) | 1831 (4.2%) | 5162 (3.9%) |
| Inflammatory diseases | 214 (7.2%) | 2766 (3.2%) | 1011 (2.3%) | 3991 (3.0%) |
| Infarct/suspicion of infarct | 33 (1.1%) | 2202 (2.5%) | 1146 (2.7%) | 3381 (2.5%) |
| Hemorrhage | 23 (0.8%) | 603 (0.7%) | 209 (0.5%) | 835 (0.6%) |
| Trauma | 50 (1.7%) | 428 (0.5%) | 91 (0.2%) | 5 (0.4%) |
| Other | 291 (9.8%) | 15,917 (18.4%) | 7407 (17.1%) | 23,615 (17.8%) |
| Not specified | 13 (0.4%) | 31 (<0.1%) | 0 (<0.1%) | 54 (<0.1%) |
| Missing | 1616 (54.3%) | 39,692 (45.8%) | 21,713 (50.3%) | 63,021 (47.4%) |
| Iodine dose | ||||
| ≤20 g | 2035 (68.3%) | 14,825 (17.1%) | 5957 (13.8%) | 22,817 (17.2%) |
| >20–40 g | 870 (29.2%) | 56,930 (65.7%) | 29,414 (68.1%) | 87,214 (65.6%) |
| >40–60 g | 70 (2.4%) | 10,834 (12.5%) | 5759 (13.3%) | 16,663 (12.5%) |
| >60 g | 3 (0.1%) | 4074 (4.7%) | 2079 (4.8%) | 6156 (4.6%) |
| Type of examination | ||||
| CT | 1297 (43.6%) | 35,293 (40.7%) | 20,898 (48.4%) | 57,488 (43.3%) |
| CT (multislice) | 730 (24.5%) | 21,968 (25.3%) | 8574 (19.8%) | 31,272 (23.5%) |
| Angiocardiography | 18 (0.6%) | 8577 (9.9%) | 3899 (9.0%) | 12,494 (9.4%) |
| Urography | 487 (16.4%) | 6659 (7.7%) | 2951 (6.8%) | 10,097 (7.6%) |
| CT (single slice) | 230 (7.7%) | 2115 (2.4%) | 670 (1.6%) | 3015 (2.3%) |
| Angiography | 25 (0.8%) | 1099 (1.3%) | 672 (1.6%) | 1796 (1.4%) |
| Phlebography | 10 (0.3%) | 212 (0.2%) | 74 (0.2%) | 296 (0.2%) |
| DSA | 9 (0.3%) | 150 (0.2%) | 62 (0.1%) | 221 (0.2%) |
| PTCA | 0 | 116 (0.1%) | 49 (0.1%) | 165 (0.1%) |
| PTA | 0 | 35 (<0.1%) | 43 (<0.1%) | 78 (<0.1%) |
| Other | 7 (0.2%) | 4464 (5.2%) | 2382 (5.5%) | 6853 (5.2%) |
| Not specified | 165 (5.5%) | 5975 (6.9%) | 2935 (6.8%) | 9075 (6.8%) |
*Multiple reasons possible.
CT, computed tomography; DSA, digital subtraction angiography; PTA, percutaneous transluminal angioplasty; PTCA, percutaneous coronary angioplasty.